Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Anticipate generic drug launch
Manage your formulary budget
Proactively manage your pharmacy inventory
|Title:||Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituent and processes for preparing thereof|
|Abstract:||The present invention relates to a novel quinolone compound having an excellent antibacterial activity. More specifically, the present invention relates to a novel quinoline(naphthyridine)carboxylic acid derivative represented by the following formula (I), which has an 4-aminomethyl-3-oximepyrrolidine substituent on 7-position of the quinolone nucleus and shows a superior antibacterial activity in contrast to the known quinolone antibacterial agents having a weak activity against gram-positive bacterial strains and also has a broad antibacterial spectrum and a highly improved pharmacokinetic property: ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and Q are defined as described in the specification.|
|Inventor(s):||Hong; Chang Y. (Daejeon, KR), Kim; Young K. (Kyungki-do, KR), Chang; Jay H. (Daejeon, KR), Kim; Se H. (Seoul, KR), Choi; Hoon (Daejeon, KR), Nam; Do H. (Daejeon, KR), Kwak; Jin H. (Daejeon, KR), Jeong; Yi N. (Daejeon, KR), Oh; Jeong I. (Daejeon, KR), Kim; Mu Y. (Daejeon, KR)|
|Assignee:||LG Chemical Ltd. (Seoul, KR)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Dosage form;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.